<DOC>
	<DOCNO>NCT02906527</DOCNO>
	<brief_summary>`` The aim study compare , real life , risk benefit ( include major bleed thrombotic event ( TE ) death cause ) associate direct oral anticoagulant ( DOAC ) anti vitamin K ( VKA ) old adult ( ≥ 75 year ) suffer nvAF . The study conduct French Health insurance database ( SNIIRAM ) . Data octo+ patient newly treat oral anticoagulant ( VKA DOAC ) non valvular atrial fibrillation ( nv AF ) collect first exposure patient drug interest inclusion period end follow-up period ( least one year follow-up patient ) . ''</brief_summary>
	<brief_title>Benefit/Risk Real Life New Oral Anticoagulants Vitamin K Antagonists Patients Aged 75 Years Over Suffering From Non Valvular Atrial Fibrillation ( nv AF )</brief_title>
	<detailed_description>`` • Context : Oral anticoagulation recommend prevention stroke thrombo-embolic event people age 80 year ( octo+ ) suffer non valvular atrial fibrillation ( nv AF ) without contraindication anticoagulant therapy . Two drug class available achieve oral anticoagulation : vitamin K antagonist ( VKA , warfarin , fluinione acenocoumarol ) Direct Oral Anticoagulants ( DOAC , dabigatran , rivaroxaban apixaban ) . The data evidence-based post-marketing literature benefit/risk ratio DOAC comparatively VKA limit , conflict , potentially bias finally inconclusive population . Nevertheless , population risk nv AF population high risk AF-related thrombotic event anticoagulant-related major bleeding . - Objectives : The aim study ass compare real benefit harm two therapeutic strategy available routine practice , anticoagulation patient 75 year old suffering nvAF . The main objective estimate compare DOAC VKA term major bleeding , thrombotic event ( TE ) death cause 75 year old suffering nv AF . The secondary objective identify factor associate occurrence event , take account type anticoagulant , identify factor associate occurrence event , take account switch VKA DOAC DOAC VKA , describe utilization pattern oral anticoagulant . - Design statistical analysis : An observational study conduct French administrative database ( SNIIRAM ) . The SNIIRAM database contain anonymous prospectively record data beneficiary ' medical reimbursement include age , gender , long-term chronic disease ( LTD ) , date death , out-hospital health-spending reimbursement patient ' hospitalization . We include octo+ patient care , newly treat ( `` new user '' ) oral anticoagulant ( VKA DOAC ) nv AF , date first prescription oral anticoagulant . From date , patient data collect least 2 year . To assess principal endpoint , estimate time date inclusion date occurrence major thromboembolic event , major bleed event , death cause , whichever come first . Exposure consider time-dependant . The total number patient expect 150 000 . ''</detailed_description>
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Vitamin K</mesh_term>
	<mesh_term>Anticoagulants</mesh_term>
	<criteria>Beneficiaries initiate treatment VKA NOAC inclusion period ( July 1 , 2011 December 31 , 2014 ) . Aged ≥ 75 year old et time OAC initiation . Presenting non valvular atrial fibrillation ( nv AF ) .</criteria>
	<gender>All</gender>
	<minimum_age>75 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Cardiology</keyword>
	<keyword>Oral anticoagulant</keyword>
	<keyword>Risk Benefit analysis</keyword>
	<keyword>Health insurance database</keyword>
	<keyword>Safety</keyword>
	<keyword>Elderly</keyword>
</DOC>